Vertex (VRTX) Stock May Sit Below Fair Value On Cash Flow
Vertex Pharmaceuticals stock has delivered a strong 5 year return of 145.1%. However, the current checks send a mixed message, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair.
- Over the past 5 years, Vertex Pharmaceuticals has returned 145.1%, which puts current investors in the position of weighing further upside against an already successful run.
- Expectations for continued cash flow generation from its existing drug portfolio can support the valuation, while any setback in pipeline progress or pricing pressure may weigh on how sustainable those cash flows look.
- The stock screens as undervalued on a DCF basis by about 31.4%. That said, the broader checks are mixed, with Vertex Pharmaceuticals scoring 3 out of 6 on valuation, which points to neither a clear bargain nor a clearly expensive stock.
The issue now is whether the current price of about US$490 per share still leaves enough margin between market value and intrinsic value for new money going into Vertex Pharmaceuticals.
Find out why Vertex Pharmaceuticals' 4.7% return over the last year is lagging behind its peers.
Is Vertex Pharmaceuticals a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach values Vertex Pharmaceuticals based on the cash it is expected to generate for shareholders. Vertex currently produces about $3.76b in free cash flow over the latest twelve months. The DCF model assumes that these cash flows keep growing rather than shrinking, which supports a higher intrinsic value than what the current price implies.
Based on these cash flow projections, the DCF model points to an estimated intrinsic value of about $715 per share. Compared with the recent market price near $490, that implies the stock screens as roughly 31.4% undervalued on a cash flow basis, even after the strong share price performance already seen.
On this cash flow view, Vertex Pharmaceuticals stock appears undervalued relative to what its projected free cash generation suggests.
Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 31.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Where Does Vertex Pharmaceuticals Sit on Earnings?
P/E is a useful cross check for Vertex Pharmaceuticals because earnings are a key focus for mature, profitable biopharma companies. Vertex trades on a P/E of about 28.7x, which sits above the broader biotech industry average of about 17.0x. It also comes in below the peer group average of about 47.7x, which suggests investors pay a premium to the sector overall but not the highest multiple in its peer set.
The fair P/E ratio from the model is about 27.8x. That is very close to the current multiple of 28.7x, so the gap is small and does not point to a clear discount or premium on earnings alone. Taken together with the DCF work, the P/E check suggests the market is roughly in line with what the model indicates investors might pay for Vertex Pharmaceuticals today.
On the P/E multiple, Vertex Pharmaceuticals stock appears priced broadly in line with what the model suggests is a fair earnings valuation.
See what the numbers say about this price — find out in our valuation breakdown.
The Vertex Pharmaceuticals Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Vertex Pharmaceuticals valuation checks leave off by spelling out which growth, margin and earnings paths would need to play out for the stock to be worth materially more or less than today’s price. Each one treats Vertex Pharmaceuticals' fair value as a thesis about how the business might develop over time, so you can see how that view holds up on the Community page.
Community views on Vertex Pharmaceuticals sit far apart, with one camp focused on an expanding kidney and gene therapy portfolio and the other worried about pricing pressure and deal risk.
Bull case: 23% undervalued
"Vertex's leadership in gene editing, showcased by the global rollout of CASGEVY and progressing assets for type 1 diabetes and kidney diseases, positions the company to capture an outsized share of the expanding gene and cell therapy market as healthcare systems worldwide increasingly prioritize transformative, curative treatments, which could translate to long-duration, high-margin revenue streams…"
Read the full Bull Case to see why Vertex Pharmaceuticals could be undervalued
Bear case: 16% overvalued
"Regulatory scrutiny over drug pricing and increasing policy reforms in key markets such as the US and Europe are expected to intensify, which could directly limit Vertex's ability to maintain premium pricing for its specialty and orphan drugs, leading to pressured revenue growth and reduced net margins over the long term…"
Read the full Bear Case to see why Vertex Pharmaceuticals could be overvalued
Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
Vertex Pharmaceuticals screens as undervalued on a Discounted Cash Flow (DCF) view, while the P/E check points to pricing that is much closer to about right. That split reflects a DCF model that leans on the durability of future free cash flows, against a market multiple that already bakes in solid expectations for earnings. With broader checks sitting in mixed territory, the key question is whether Vertex Pharmaceuticals can sustain and grow its cash generation without running into material pricing or pipeline setbacks. How that trade off plays out is likely to determine whether the current discount is attractive or justified.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com